CHINARES PHARMA (03320) dropped close to 3%, declining by 1.98% to HK$4.46 at the time of writing, with a turnover of HK$25.1648 million. The decline follows an announcement from CHINARES PHARMA, stating that on January 30, 2026, China Resources Boya Bio-Pharmaceutical Group Co.,Ltd. released its annual performance forecast for the period ending December 31, 2025. The forecast indicates that the net profit attributable to shareholders of China Resources Boya Bio-Pharmaceutical for the year ending December 31, 2025, is expected to be approximately RMB 105 million to RMB 136.5 million, a significant decrease compared to the net profit of about RMB 397 million in the same period last year. Furthermore, the net loss attributable to shareholders after deducting non-recurring gains and losses is projected to be between RMB 7.5 million and RMB 15 million, contrasting sharply with a net profit of approximately RMB 302 million in the prior-year period. The announcement attributed this performance to the company's blood products business being adversely affected by several factors, including the expansion of centralized procurement, DRG/DIP reforms, medical insurance cost controls, and increased regulatory focus on rational drug use. These factors have led to a reduction in clinical prescriptions and a decline in demand for its blood products. Simultaneously, intensifying market competition resulted in a year-on-year decrease in the gross profit margin of China Resources Boya Bio-Pharmaceutical's blood products business during the reporting period.